Search: WFRF:(Cornel Jan H.)
> (2020-2021)
> Michelsen Annika E. >
ALCAM predicts futu...
ALCAM predicts future cardiovascular death in acute coronary syndromes : Insights from the PLATO trial
-
Ueland, Thor (author)
-
- Åkerblom, Axel, 1977- (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi,kardiologi
-
- Ghukasyan, Tatevik (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),UCR
-
show more...
-
Michelsen, Annika E (author)
-
Becker, Richard C (author)
-
Bertilsson, Maria (author)
-
Budaj, Andrzej (author)
-
Cornel, Jan H (author)
-
Himmelmann, Anders (author)
-
- James, Stefan, 1964- (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
-
- Siegbahn, Agneta, 1947- (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Klinisk kemi,UCR
-
Storey, Robert F (author)
-
Kontny, Frederic (author)
-
Aukrust, Pål (author)
-
- Wallentin, Lars, 1943- (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi,UCR
-
show less...
-
(creator_code:org_t)
- Elsevier, 2020
- 2020
- English.
-
In: Atherosclerosis. - : Elsevier. - 0021-9150 .- 1879-1484. ; 293, s. 35-41
- Related links:
-
https://munin.uit.no...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- BACKGROUND AND AIMS: Activated leukocyte cell adhesion molecule (ALCAM) is upregulated during inflammation and involved in transmigration of leukocytes and T-cell activation. We hypothesized that ALCAM might be associated with recurrent events in patients with acute coronary syndromes (ACS).METHODS: ALCAM was measured in serum obtained on admission, at discharge, 1 month and 6 months in a subgroup of 5165 patients admitted with ACS and included in the PLATelet inhibition and patient Outcomes (PLATO) trial (NCT00391872). The association between ALCAM and the composite endpoint and its components, including cardiovascular (CV) death, non-procedural spontaneous myocardial infarction (MI) or stroke during 1-year follow-up, was assessed by Cox proportional hazards models with incremental addition of clinical risk factors and biomarkers (including high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15).RESULTS: The median (Q1-Q3) concentration of ALCAM at admission was 97 (80-116) ng/mL. A 50% higher level of ALCAM on admission was associated with a hazard ratio (HR) of 1.16 (95% confidence interval [1.00-1.34] p = 0.043) for the composite endpoint in fully adjusted analysis, mainly driven by the association with CV death (HR 1.45 [1.16-1.82] p = 0.0012).CONCLUSIONS: In patients with ACS, admission level of ALCAM was independently associated with adverse outcome including CV death even after adjustment for established inflammatory and cardiac biomarkers.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Activated leukocyte cell adhesion molecule
- Acute coronary syndromes
- CV death
- Prognosis
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Ueland, Thor
-
Åkerblom, Axel, ...
-
Ghukasyan, Tatev ...
-
Michelsen, Annik ...
-
Becker, Richard ...
-
Bertilsson, Mari ...
-
show more...
-
Budaj, Andrzej
-
Cornel, Jan H
-
Himmelmann, Ande ...
-
James, Stefan, 1 ...
-
Siegbahn, Agneta ...
-
Storey, Robert F
-
Kontny, Frederic
-
Aukrust, Pål
-
Wallentin, Lars, ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
Atherosclerosis
- By the university
-
Uppsala University